Table 3.
Adjusted association of individual direct-acting oral anticoagulant (DOAC) drug with outcomes relative to warfarina
| Warfarin | Apixaban | Dabigatran | Rivaroxaban | |
|---|---|---|---|---|
| Number of patients | 3431 | 1830 | 526 | 1874 |
| Ischemic stroke or systemic embolism (primary outcome) | ||||
| Total person time follow up | 3525.39 | 1357.01 | 730.25 | 2081.99 |
| Events per 100 patient years, n (95% CI) | 1.19 (0.86, 1.61) | 1.25 (0.73, 2.01) | 1.23 (0.56, 2.34) | 1.25 (0.82, 1.83) |
| Unadjusted HR (95% CI) | Reference | 1.09 (0.62, 1.91) | 1.10 (0.54, 2.25) | 1.14 (0.70, 1.86) |
| IPTW adjusted HR (95% CI) | Reference | 1.22 (0.65, 2.28) | 1.19 (0.56, 2.51) | 1.14 (0.66, 1.98) |
| E-value for IPTW adjusted HR | - | 1.74 | 1.67 | 1.54 |
| Major bleeding (primary outcome) | ||||
| Total person time follow up | 3406.55 | 1346.42 | 697.19 | 2036.6 |
| Events per 100 patient years, n (95% CI) | 4.49 (3.81, 5.26) | 2.45 (1.69, 3.44) | 3.87 (2.55, 5.64) | 3.19 (2.46, 4.07) |
| Unadjusted HR (95% CI) | Reference | 0.48 (0.33, 0.70) | 1.03 (0.68, 1.55) | 0.76 (0.57, 1.02) |
| IPTW adjusted HR (95% CI) | Reference | 0.57 (0.38, 0.86) | 0.84 (0.52, 1.36) | 0.82 (0.60, 1.12) |
| E-value for IPTW adjusted HR | - | 2.90 | 1.67 | 1.74 |
| All-cause death (secondary outcome) | ||||
| Total person time follow up | 3539.03 | 1360.79 | 738.83 | 2093.24 |
| Events per 100 patient years, n (95% CI) | 13.3 (12.1, 14.6) | 8.23 (6.78, 9.90) | 5.41 (3.87, 7.37) | 6.93 (5.85, 8.15) |
| Unadjusted HR (95% CI) | Reference | 0.52 (0.42, 0.64) | 0.45 (0.33, 0.62) | 0.52 (0.43, 0.63) |
| IPTW adjusted HR (95% CI) | Reference | 0.70 (0.56, 0.87) | 0.68 (0.51, 0.90) | 0.67 (0.55, 0.81) |
| E-value for IPTW adjusted HR | - | 2.21 | 2.30 | 2.35 |
| Cardiovascular death (secondary outcome) | ||||
| Total person time follow up | 3539.03 | 1360.79 | 738.83 | 2093.24 |
| Events per 100 patient years, n (95% CI) | 3.14 (2.58, 3.78) | 2.35 (1.61, 3.32) | 2.17 (1.24, 3.52) | 1.48 (1.01, 2.10) |
| Unadjusted HR (95% CI) | Reference | 0.69 (0.46, 1.03) | 0.80 (0.47, 1.34) | 0.49 (0.33, 0.73) |
| IPTW adjusted HR (95% CI) | Reference | 0.86 (0.53, 1.40) | 1.10 (0.68, 1.77) | 0.62 (0.40, 0.95) |
| E-value for IPTW adjusted HR | - | 1.60 | 1.43 | 2.61 |
Abbreviations: CI confidence interval, HR hazard ratio, IPTW inverse probability of treatment weighting
a
Very few people received edoxaban. Therefore, we did not compare edoxaban vs. warfarin.